The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.新加坡博彩公司（www.99cx.vip）是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。新加坡博彩公司上最新新加坡博彩公司登录线路、新加坡博彩公司代理网址更新最快。新加坡博彩公司开放皇冠官方会员注册、皇冠官方代理开户等业务。
PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.
The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.
The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.
The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.,
Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.
Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.
UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg
转载说明:本文转载自Sunbet。 欧博开户声明:该文看法仅代表作者自己，与本平台无关。转载请注明：新2网址最新登录:Sanofi ends cancer drug trials